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AJH 2004; 17:660–667Background: Increase in left ventricular mass (LVM)
may be linked to morbidity and mortality in hypertensive
patients. Arterial stiffness, systolic blood pressure (BP),
and pulse pressure (PP) seem to be the main determinants
of LVM. The perindopril/indapamide combination nor-
malizes systolic BP, PP, and arterial function to a greater
extent than atenolol. The aim of this study was to compare
the effects of perindopril (2 mg)/indapamide (0.625 mg)
first-line combination with atenolol (50 mg) on LVM
reduction in hypertensive patients.
Methods: Two hundred fourteen patients with essential
hypertension participating in the PREterax in Regression of
Arterial Stiffness in a ContrOlled Double-BliNd (REASON),
randomized, double-blind, parallel-group study, underwent
M-mode two-dimensional-guided echocardiography.
Results: Perindopril/indapamide and atenolol were both
effective at brachial BP reduction during the 12-month pe-
riod. The systolic BP reduction was significantly greater with
perindopril/indapamide than with atenolol (21.2 v 15.3
mm Hg), whereas the reduction in diastolic BP was similar0895-7061/04/$30.00
doi:10.1016/j.amjhyper.2004.03.681between treatment groups (12.1 v 11.3 mm Hg). Reduc-
tion in LVM was higher with perindopril/indapamide than
with atenolol. The between-group difference was significant
for LVM (13.6 v 4.3 g, P  .027), LVM/body surface
area (LVMI1, P  .032), and LVM/body height2.7 (LVMI2,
P .013). The 124 patients with LV hypertrophy at baseline
showed greatest LVM regression (LVM: 22.5 v 8.9 g, P
 .009; LVMI1, P .031; LVMI2, P .028). The reduction
in LVM adjusted for brachial systolic BP and heart rate was
still significantly greater with perindopril/indapamide than
with atenolol.
Conclusions: Treatment, based on a first-line perindo-
pril/indapamide combination in hypertensive patients, was
more effective than atenolol on regression of echocardio-
graphic indices of LVM and LV hypertrophy. Am J Hy-
pertens 2004;17:660–667 © 2004 American Journal of
Hypertension, Ltd.
Key Words: Hypertension, left ventricular hypertro-
phy, left ventricular mass, echocardiography, perindopril/
indapamide combination.I t is well established that hypertension, defined assystolic blood pressure (BP) 140 mm Hg or dia-stolic BP 90 mm Hg,1–3 represents a major risk
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661AJH–August 2004–VOL. 17, NO. 8 LVM REDUCTION ON PERINDOPRIL/INDAPAMIDEies as well as recommendations from hypertension guide-
lines have shown that the brachial systolic BP is a better
guide for evaluating cardiovascular risk than brachial di-
astolic BP.2–5 Pulse pressure (PP) and arterial stiffness
may also be independent cardiovascular risk factors.6–10
Hypertensive patients with concurrent cardiovascular
structural changes such as left ventricular hypertrophy (LVH)
have a greater mortality risk than those with hypertension
alone.11–14 There is evidence to suggest that a parallel cardiac
and vascular adaptation exists in arterial hypertension15 with
a positive relationship between cardiac mass and arterial
stiffness.16 A direct relationship between cardiac mass and
BP has been demonstrated, and the main pressure determi-
nants of left ventricular mass (LVM) in essential hyperten-
sion are systolic BP and PP.7,17–23 Reduced aortic
distensibility and compliance may participate in the genesis
of cardiac hypertrophy in hypertension. Arterial compliance
also determines the pulsatile amplitude of the pressure wave
and its reduction induces a selective increase in systolic level
and PP. Consequently a different response after antihyperten-
sive treatment has been demonstrated in cardiac and arterial
changes.24,25
A first-line combination of the angiotensin-converting
enzyme (ACE) inhibitor perindopril (2 mg) and indapam-
ide (0.625 mg), a sulphamoyl diuretic that belongs to the
thiazide group, has been shown to have a favorable effi-
cacy:safety ratio26,27 and superior antihypertensive effi-
cacy in comparison with enalapril, losartan, and
irbesartan.28–30 Recently, PREterax in Regression of Ar-
terial Stiffness in a ContrOlled Double-BliNd Study
(REASON) has shown that the perindopril/indapamide
antihypertensive treatment normalized systolic BP, PP,
and arterial function to a greater extent than atenolol in
hypertensive patients.31 Moreover, the perindopril/indap-
amide combination has shown a beneficial effect on car-
diac hypertrophy and capillary density in experimental
hypertension.32 Given such findings it is timely to com-
pare cardiac mass structural changes after perindopril/
indapamide combination or atenolol in the treatment of
hypertensive patients.
In this article we present the results from the REASON
echocardiography ancillary study. This study investigated
the long-term effects of perindopril/indapamide first-line
combination compared with atenolol on echocardio-
graphic indices of LVM in hypertensive patients.
Methods
Study Design
The REASON study was a 12-month, randomized, dou-
ble-blind, parallel-group study conducted in 13 countries,
which has previously been published.31 REASON com-
pared the efficacy and safety of perindopril (2 mg)/ inda-
pamide (0.625 mg) or atenolol (50 mg) in the treatment of
471 patients with essential hypertension.
Men and women aged 18 to 84 years, with a diagnosis
of uncomplicated essential hypertension (systolic BP160 mm Hg and 210 mm Hg; diastolic BP 95 mm
Hg and 110 mm Hg), were eligible for inclusion.
After a 4-week placebo wash-out period, patients were
randomized to receive one capsule of perindopril (2 mg)/
indapamide (0.625 mg) or atenolol (50 mg) once daily for
12 months. After 3 months of treatment and then at every
3-month period until the end of the study, the dose could
be increased to two tablets per day if the systolic BP
remained 160 mm Hg or the diastolic BP 90 mm Hg
(n  103 perindopril/ indapamide and 92 for atenolol; log
rank test P not significant [NS]). Other antihypertensive
drugs were not allowed during the study follow-up. At
study end, dosage was progressively decreased during 8 to
15 days to avoid any complications that might result from
abrupt atenolol withdrawal. This study was performed in
accordance with the Declaration of Helsinki, the protocol
was approved by the Ethic Committees according to na-
tional regulations, and all patients provided written in-
formed consent to participate.
Patients who participated in the echocardiography
study (n  214) had an echocardiogram recorded at base-
line (month 0) and after 12 months of effective treatment
(end value).
Efficacy Assessments
Left ventricular dimensions were assessed using two-di-
mensionally directed M-mode echocardiography. A qual-
ity control procedure was established for the validation of
the echocardiographic evaluations. Each examination was
recorded on S-VHS tape and readings of the measure-
ments were performed centrally, on five cycles by two
experienced physician readers blind to treatment, patients,
and visit, and the values of both readers were then aver-
aged.
Echocardiographic measurements (left ventricular in-
ternal dimension [LVID], posterior wall thickness [PWT],
and interventricular septum thickness [IVST]) were as-
sessed at the end of diastole, defined as the peak of the R
wave of the QRS complex, and in accordance with the
recommendations of the American Society of Echocardi-
ography.33 The intraobserver and interobserver reproduc-
ibility of the echocardiographic measurements was tested
in a parallel series of 10 subjects with three replications,
the methodology of which is described in detail else-
where.34,35 The coefficient of variation was below 3%, the
intraobserver correlation was r  0.99 mm, and the inter-
observer correlation was r  0.96 mm (mean difference,
0.05  0.03 mm).
The LVM was calculated from the Penn convention
according to the standard Devereux formula36: LVM (g)
1.04 [(IVSTd  PWTd  LVIDd)3  LVIDd3]  13.6,
and converted into LVM index (LVMI1) by dividing by
body surface area. Due to a possible overcalculation in
overweight patients, LVM divided by body height2.7 was
also calculated (LVMI2).37
Brachial systolic BP, diastolic BP, and heart rate were
determined after a 10-min rest in the supine position using
662 AJH–August 2004–VOL. 17, NO. 8LVM REDUCTION ON PERINDOPRIL/INDAPAMIDEa mercury sphygmomanometer and stethoscope. Brachial
PP was calculated from individuals’ values of systolic BP
and diastolic BP.
Tolerability Assessments
Any adverse events were recorded at clinic visits. Varia-
tions in laboratory parameters were measured between
baseline and end values. Tolerability data are presented for
the entire REASON study population.
Statistical Analyses
All analyses were performed using SAS software version
8.2 (SAS Institute, Cary, NC). Quantitative variables are
presented as mean changes (with standard deviation) from
baseline to end value, unless otherwise stated. Patients
who received at least one dose of treatment were included
in an intent-to-treat analysis. A last observation carried
forward approach was used if data were missing. Patients
with LVH at baseline (LVMI1 100 g/m2 for women and
120 g/m2 for men) were included in a per-protocol
subgroup analysis prespecified in the protocol.
Within-group effect was assessed using a two-tailed
Student t test for paired samples. Between-group compar-
isons were assessed on the change at last evaluation using
a covariance analysis, which included the treatment group
as a factor, and age, sex, and the baseline value of the
variable as covariates. A 5% threshold was considered
significant. The relationship between LVM parameters and
influence parameters was investigated using a stepwise
linear regression procedure.
Results
Patient Characteristics
A total of 214 randomized patients, including 124 patients
with LVH, were recruited to the echocardiography study.
The baseline characteristics (Table 1) were similar in the
Table 1. Baseline characteristics for patients includ
All Patients (n
Per/Ind
(n  110)
Sex (M:W) (%) 61:39
Age (y) 53.2 (11.8)
BMI (kg/m2) 26.7 (2.8)
Systolic BP (mm Hg) 162.1 (13.7)
Diastolic BP (mm Hg) 99.0 (7.0)
Mean BP (mm Hg) 120.0 (6.7)
Pulse pressure (mm Hg) 63.1 (15.0)
Heart rate (beats/min) 72.7 (10.4)
BMI  body mass index; BP  blood pressure; Per/Ind  perindopr
Mean (SD) values presented unless otherwise stated.two treatment groups and did not differ from those of theentire population.31 Seventy-eight percent of patients com-
pleted 12 months of treatment. Forty-eight patients with-
drew, 21 in the perindopril/indapamide group and 27 in the
atenolol group because of adverse events (10 v 11, respec-
tively), lack of efficacy (4 v 11), major protocol violations
(1 v 2), and nonmedical reasons (6 v 3). Overall, the mean
exposure to study drug was 312.3 days.
Brachial BP Assessment
Perindopril/indapamide and atenolol were both effective at
BP reduction during the 12-month period. However, re-
duction in systolic BP was significantly greater with per-
indopril/indapamide than with atenolol (21.2 v 15.3
mm Hg, respectively; P  .01). Significant reductions in
diastolic BP were achieved in both treatment groups, but
with no significant between-group differences (12.1 v
11.3 mm Hg). The PP reduction was significantly
greater for the perindopril/indapamide group than for the
atenolol group (9.1 v 4.0 mm Hg; P  .01). As
expected, heart rate was lowered to a significantly greater
extent with atenolol than perindopril/indapamide (6.7 v
2.5 beats/min; P  .001; Table 2).
Echocardiographic Assessments
Left ventricular diameter, thickness, and mass did not
differ between the two treatment groups at baseline (Table
3). At the end of the treatment period LVID, PWT, and
IVST were all significantly reduced in the perindopril/
indapamide group. There was no significant difference
with atenolol (LVID: 0.62 v 0.02 mm; PWT: 0.29 v
0.10 mm; IVST: 0.22 v 0.12 mm, respectively;
Table 3).
Consequently, LVM was considerably more reduced
with the perindopril/indapamide than with atenolol. The
between-group difference was significant, irrespective of
whether this indice was expressed as LVM (13.6 v 4.3
g; P  .05), LVMI1 (6.6 v 2.1 g/m2; P  .05), or
2.7
in the study
214)
Left Ventricular Hypertrophy
Patients (n  124)
tenolol
 104)
Per/Ind
(n  70)
Atenolol
(n  54)
68:32 57:43 63:37
.7 (11.4) 54.3 (11.5) 51.8 (12.1)
.8 (2.9) 26.8 (3.0) 26.9 (2.7)
.5 (16.2) 162.0 (13.6) 162.7 (15.6)
.3 (7.3) 98.8 (7.0) 100.0 (7.8)
.0 (7.9) 119.9 (6.3) 120.9 (7.9)
.2 (16.5) 63.2 (15.5) 62.8 (16.4)
.8 (7.9) 72.8 (11.0) 71.1 (7.1)
apamide combination.ed

A
(n
53
26
161
99
120
62
71
il/indLVMI2 (3.3 v 0.9 g/m ; P  .05, respectively).
663AJH–August 2004–VOL. 17, NO. 8 LVM REDUCTION ON PERINDOPRIL/INDAPAMIDEPatients with LVH at baseline demonstrated an even
greater regression in LVM (LVM: 22.5 v 8.9 g;
LVMI1 11.3 v 5.3 g/m2, respectively; Table 4, Fig. 1).
The relationship between LV mass reduction and influ-
ence parameters was investigated using a stepwise linear
regression procedure. Last step with systolic BP and heart
rate for covariates showed that between treatment groups
difference in adjusted mean LVM reduction was still sig-
nificant (LVM 8.7, P  .034). Systolic BP variation
estimate was 0.23 and the statistical significance was bor-
Table 2. Blood pressure (BP) changes, comparison
All Patients (n
Per/Ind
(n  110)
Systolic BP (mm Hg)
Baseline 162.1 (13.7)
End value 140.8 (15.2)
Change 21.2 (14.9)§ 
Difference* (SE) 5.7 (2.2
Diastolic BP (mm Hg)
Baseline 99.0 (7.0)
End value 86.9 (9.0)
Change 12.1 (8.9)§ 
Difference* (SE) 0.9 (1.2
Pulse pressure (mm Hg)
Baseline 63.1 (15.0)
End value 53.9 (13.1)
Change 9.1 (11.5)§
Difference* (SE) 5.1 (1.8)
Abbreviations as in Table 1.
* Adjusted for baseline; † P  .05; ‡ P  .01; § P  .001; ns  no
difference values].
Mean (SD) values presented unless otherwise stated.
Table 3. Changes in left ventricular morphology fr
All Patients (n  214
Per/Ind
(n  110)
Ate
(n 
LVID (mm)
Baseline 49.98 (3.79) 50.72
End 49.36 (3.86) 50.70
Change 0.62 (1.97)† 0.02
PWT (mm)
Baseline 10.04 (1.12) 9.83
End 9.75 (1.03) 9.73
Change 0.29 (0.79)‡ 0.10
IVST (mm)
Baseline 11.57 (1.70) 11.18
End 11.35 (1.60) 11.06
Change 0.22 (0.76)† 0.12
IVST  interventricular septal thickness; LVID  left ventricular inte
in Table 1.
* P  .05; † P  .01; ‡ P  .001; ns  not significant [versus bas
Mean (SD) values presented.derline (P .060). Heart rate variation was not significant
(estimate 0.02, P  .92).
Tolerability
Tolerability was assessed for the entire REASON popula-
tion (n 471). Both treatments were well tolerated and no
differences in the incidence of side effects were reported.
The most frequently reported adverse events (all occurring
at 5%) were headache, dizziness, asthenia, and cough.31
ween the two treatments
14)
Left Ventricular Hypertrophy
Patients (n  124)
enolol
 104)
Per/Ind
(n  70)
Atenolol
(n  54)
5 (16.2) 162.0 (13.6) 162.7 (15.6)
2 (22.3) 139.3 (13.9) 145.1 (20.7)
3 (18.2)§ 22.7 (14.0)§ 17.6 (18.4)§
5.4 (2.7)†
.3 (7.3) 98.8 (6.8) 10.0 (7.8)
0 (11.0) 85.8 (8.6) 87.8 (10.8)
3 (9.9)§ 13.0 (6.9)§ 12.2 (9.8)§
1.1 (1.5)ns
2 (16.5) 63.2 (15.5) 62.8 (16.4)
2 (17.0) 53.5 (12.4) 57.4 (16.7)
0 (14.6)‡ 9.7 (11.1)§ 5.4 (16.4)†
4.3 (2.5)ns
nificant [versus baseline for change values and between groups for
aseline to end value
Left Ventricular Hypertrophy
Patients (n  124)
l
4)
Per/Ind
(n  70)
Atenolol
(n  54)
4) 50.56 (3.29) 51.72 (3.84)
1) 49.68 (3.29) 51.56 (3.98)
1)ns 0.88 (2.06)‡ 0.17 (1.87)ns
4) 10.46 (1.01) 10.24 (0.95)
6) 9.91 (1.02) 10.00 (0.86)
2)ns 0.55 (0.76)‡ 0.24 (0.70)*
5) 12.04 (1.70) 11.57 (1.31)
7) 11.68 (1.69) 11.36 (1.29)
4)ns 0.36 (0.79)‡ 0.21 (0.79)ns
dimension; PWT  posterior wall thickness; other abbreviations as
for change values].bet
 2
At
(n
161.
146.
15.
)‡
99
88.
11.
)ns
62.
58.
4.
‡
t sigom b
)
nolo
10
(4.5
(4.1
(2.7
(1.0
(0.9
(0.6
(1.3
(1.3
(0.8
rnal
eline
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adverse events was similar between atenolol and perindo-
pril/indapamide (11 v 10, respectively).
Discussion
In this REASON echocardiography study, the first-line
combination perindopril/indapamide was superior to
atenolol in regression of echocardiographic indices of
LVM, as shown by the significant reductions in LVM,
LVM/body surface area, and LVM/body height2.7. These
benefits were more pronounced in patients who had LVH
at entry. Reduction in systolic BP was significantly greater
with perindopril/indapamide than with atenolol, whereas
the reductions in diastolic BP were similar between treat-
ment groups. The results are robust as the study design
complies with criteria for informative trials on LVH re-
gression,38 namely, sufficient number of subject (214),
representative population, long study duration (12
months), double-blind randomization, and blinded echo-
cardiographic readings. On average, atenolol decreased
heart rate significantly more than the combination of per-
indopril/indapamide. Nevertheless, the distribution of the
individual heart rates was great and the intersection be-
tween the values under atenolol and the values without
atenolol was large. The blindness to treatment, patient, and
visits could be considered as sufficient to avoid a strong
probability that the reader could guess from which treat-
ment group a tracing came. Antihypertensive drugs other
than the randomized treatments were not allowed during
Table 4. Left ventricular mass indices changes, co
All Patients (n  2
Per/Ind
(n  110)
A
(n
LVM (g)
Baseline 241.68 (58.07) 238.0
End value 228.09 (51.67) 233.6
Change 13.58 (28.88)§ 4.3
Difference* (SE) 7.88 (3.55)†
LVMI1 (g/m
2)
Baseline 128.22 (26.58) 126.5
End value 121.61 (23.82) 124.4
Change 6.61 (15.64)§ 2.0
Difference* (SE) 4.03 (1.86)†
LVMI2 (g/m
2.7)
Baseline 58.10 (12.76) 57.3
End value 54.83 (11.31) 56.4
Change 3.27 (6.98)§ 0.9
Difference* (SE) 2.22 (0.89)†
LVM  left ventricular mass; LVMI1  left ventricular mass/body su
as in Table 1.
* Adjusted for age, sex, and baseline.
Within group comparisons for change value and between group c
not significant.
Mean (SD) values presented unless otherwise statedthe study and the comparison between the treatmentgroups reflects only the difference between treatment with
the perindopril/indapamide combination and treatment
with atenolol.
These results are consistent with previous studies sug-
gesting that some antihypertensive drugs may reverse
LVM more effectively than others. A meta-analysis39
shows that after correction for BP, LVM regression is
more evident with ACE inhibitors than with other antihy-
pertensive agents. The Losartan LVH Regression
(REGAAL) study40 compared treatment with either an
angiotensin II antagonist (losartan) or atenolol in 225
hypertensive patients with LVH during a 36-week period.
The reduction in LVMI was 4.5 g/m2 with atenolol and
7.4 g/m2 with losartan. In our study the reduction in
LVMI with atenolol was similar (5.3 g/m2) taking into
account the longer study duration (48 weeks).
The larger reduction after treatment with perindopril/
indapamide (11.3 g/m2) could be due to the specific
effect of this combination. A direct beneficial effect of
treatment on myocyte hypertrophy, myocardial fibrosis
periarteriolar, total interstitial collagen, structural and
functional coronary microcirculation, or vascular thick-
ness are possible explanations.32,41–43
The greater effect of perindopril/indapamide on bra-
chial systolic BP could explain its superior effect on LVM
reduction, as the main pressure determinants of LVM are
systolic BP and PP.21–23 Moreover, the lowering heart rate
effect of atenolol might also modify LVM.44 Nevertheless,
to assess the effect on LVM beyond the peripheral hemo-
rison between the two treatments
Left Ventricular Hypertrophy
Patients (n  124)
olol
04)
Per/Ind
(n  70)
Atenolol
(n  54)
5.84) 259.77 (51.33) 258.20 (49.64)
1.90) 237.26 (45.16) 249.28 (47.06)
8.05)ns 22.51 (28.06)§ 8.92 (26.83)†
11.95 (4.49)‡
5.20) 138.39 (21.71) 137.45 (21.60)
2.95) 127.10 (19.91) 132.13 (21.34)
4.47)ns 11.29 (15.43)§ 5.32 (15.06)*
5.58 (2.55)†
2.27) 63.10 (11.31) 62.54 (11.17)
1.75) 57.67 (10.25) 60.45 (11.09)
.21)ns 5.43 (6.76)§ 2.09 (6.79)†
3.14 (1.15)‡
area; LVMI2  left ventricular mass/height
2.7; other abbreviations
risons for difference value: † P  .05; ‡ P  .01; § P  .001; ns mpa
14)
ten
 1
1 (5
6 (5
4 (2
2 (2
8 (2
5 (1
1 (1
0 (1
2 (7
rface
ompadynamic changes, the tests were adjusted for brachial
665AJH–August 2004–VOL. 17, NO. 8 LVM REDUCTION ON PERINDOPRIL/INDAPAMIDEsystolic BP and heart rate variation without altering the
difference (8.7 mm; P  .05), which can, therefore, be
considered to reflect differences in the two drugs that are
independent of their ability to lower brachial systolic BP
or heart rate.
The main REASON results31,45 demonstrated that per-
indopril/indapamide reduced central (carotid) and periph-
eral (brachial) systolic BP and PP to a significantly greater
extent than atenolol, and that these benefits were more
pronounced for central systolic BP and PP. Perindopril/
indapamide attenuated carotid wave reflections to a greater
extent than atenolol, which accounted for the beneficial
effects on central systolic BP and PP. Given that LVM is
affected more by central rather than peripheral hemody-
namic changes, the more pronounced effects of perindo-
pril/indapamide on central systolic BP and PP lowering
could explain its greater effect on LVM reduction. It has
already been demonstrated that aortic impedance15,16 and
PP amplification7,17–19,21–23 are involved in cardiovascular
factors influencing LVM, and that the effects of antihy-
pertensive agents on these parameters may differ accord-
ing to the drug involved.46
It will be interesting to determine whether the specific
effect of the perindopril/ indapamide combination on LVM
regression will result in morbidity and mortality reduction
over that observed with adequate BP control. The effect of
FIG. 1. Change from baseline to end value for left ventricular in-
ternal dimension (LVID), posterior wall thickness (PWT), interven-
tricular septum thickness (IVST) and left ventricular mass (LVM) for
patients with left ventricular hypertrophy (n  124). Mean  SE.
Shaded bars  perindopril/indapamide combination; open bars 
atenolol. *P  .05; ***P  .001; ns  not significant.the perindopril/indapamide combination on morbidity and
mortality is the subject of an ongoing double-blind con-
trolled study in more than 10,000 subjects,49 the main
results of which are expected in 2006. The study of LVM
in the Hypertensive Subject (MAVI)47 showed that ele-
vated LVM is a cardiovascular disease risk independently
of brachial systolic BP. In the Losartan Intervention for
Endpoint Reduction (LIFE) study, after adjustment for
treatment and other factors, regression of LVH was found
to be associated with an improved prognosis indepen-
dently of brachial BP.48
In conclusion, the findings have shown that the first-
line combination perindopril (2 mg)/indapamide (0.625
mg) was more effective than atenolol in systolic BP and PP
reduction and improvement of LVM parameters, during a
12-month treatment period. Perindopril/indapamide may
be a valuable treatment choice, with a view to reducing the
long-term morbidity and mortality risks associated with
hypertension or LVH.
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